A detailed history of Marshall Wace, LLP transactions in Liquidia Corp stock. As of the latest transaction made, Marshall Wace, LLP holds 45,454 shares of LQDA stock, worth $454,994. This represents 0.0% of its overall portfolio holdings.

Number of Shares
45,454
Holding current value
$454,994
% of portfolio
0.0%

Shares

6 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 14, 2024

BUY
$11.96 - $15.71 $543,629 - $714,082
45,454 New
45,454 $545,000
Q3 2022

Nov 14, 2022

BUY
$3.73 - $8.39 $170,886 - $384,379
45,814 New
45,814 $249,000
Q2 2021

Aug 13, 2021

SELL
$2.51 - $3.11 $30,797 - $38,159
-12,270 Closed
0 $0
Q1 2021

May 17, 2021

BUY
$2.42 - $3.6 $29,693 - $44,172
12,270 New
12,270 $33,000
Q2 2019

Aug 14, 2019

SELL
$7.92 - $11.39 $22,160 - $31,869
-2,798 Closed
0 $0
Q1 2019

May 14, 2019

BUY
$10.82 - $21.79 $30,274 - $60,968
2,798 New
2,798 $32,000

Others Institutions Holding LQDA

About Liquidia Corp


  • Ticker LQDA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 64,362,300
  • Market Cap $644M
  • Description
  • Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for unmet patient needs in the United States. Its product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension. It also distributes generic treprostinil inje...
More about LQDA
Track This Portfolio

Track Marshall Wace, LLP Portfolio

Follow Marshall Wace, LLP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Marshall Wace, LLP, based on Form 13F filings with the SEC.

News

Stay updated on Marshall Wace, LLP with notifications on news.